Drug Profile
Research programme: Niemann-Pick disease therapeutics - Biovista/Wylder Nation Foundation
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Wylder Nation Foundation
- Class
- Mechanism of Action Sphingolipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Niemann-Pick disease type A
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Niemann-Pick-disease-type-A in USA
- 24 Sep 2015 Biovista and Wylder Nation Foundation agree to co-develop in USA for Niemann-Pick disease type A
- 02 Sep 2015 Early research in Niemann-Pick disease type A in USA (unspecified route)